Efforts have been made to develop therapeutics targeting soluble and insoluble Aβ or the enzymes responsible for amyloid precursor protein (APP) cleavage as potential AD treatments, albeit with disappointing outcomes [21]. Here, APP is linked to Alzheimer disease.